Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)

Autor: Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., Ferguson, V., Seckl, M. J.

Publikováno v: Nature Communications, 14(1):260. Nature Publishing Group UK
Coombes, R C, Badman, P D, Lozano-Kuehne, J P, Liu, X, Macpherson, I R, Zubairi, I, Baird, R D, Rosenfeld, N, Garcia-Corbacho, J, Cresti, N, Plummer, R, Armstrong, A, Allerton, R, Landers, D, Nicholas, H, McLellan, L, Lim, A, Mouliere, F, Pardo, O E, Ferguson, V & Seckl, M J 2023, ' Author Correction : Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0) ', Nature Communications, vol. 14, no. 1, 260 . https://doi.org/10.1038/s41467-023-35969-4

In the original version of this article, the following author (Veronica Ferguson) was omitted from the author list. Author list, Author contributions and competing interests statements have now been updated in both the PDF and HTML versions of the ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7e2e046860bc756a455c52bf62b45aab
https://research.vumc.nl/en/publications/b3ee0e28-5d1b-4b34-b1e8-b9b33e588db9

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Autor: R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, V. Ferguson, M. J. Seckl

Publikováno v: Nature Communications, 13(1):3246. Nature Publishing Group UK
Coombes, R C, Badman, P D, Lozano-Kuehne, J P, Liu, X, Macpherson, I R, Zubairi, I, Baird, R D, Rosenfeld, N, Garcia-Corbacho, J, Cresti, N, Plummer, R, Armstrong, A, Allerton, R, Landers, D, Nicholas, H, McLellan, L, Lim, A, Mouliere, F, Pardo, O E & Seckl, M J 2022, ' Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer ', Nature Communications, vol. 13, no. 1, 3246 . https://doi.org/10.1038/s41467-022-30666-0, https://doi.org/10.1038/s41467-022-30666-0

We conducted a phase IIa, multi-centre, open label, single arm study (RADICAL; NCT01791985) of AZD4547 (a potent and selective inhibitor of Fibroblast Growth Factor Receptor (FGFR)-1, 2 and 3 receptor tyrosine kinases) administered with anastrozole o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf41360879c66a88fb3325689e8e6361